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Conducting randomised controlled trials in the palliative-care
patient population is a challenge. It is difficult to recruit patients
and to conduct trials successfully due to the serious nature of the
illness and the inevitability of symptom progression.
Pain trials are especially prone to error. Pain is a subjective
experience and as such is influenced by a number of variables that
are difficult to control, both in the clinical situation, and in the
context of a controlled trial. Psychological factors such as anxiety
and depression may influence the perception of pain and even the
effect of opioids (Wasan et al, 2005). A critical review of the
literature on cancer pain found strong evidence for a relationship
between psychosocial factors and chronic cancer pain (Zaza and
Baine, 2002). The authors concluded that cancer pain assessment
should include routine screening for psychological distress.
Cognitive style such as catastrophising may also contribute to
the intensity of pain (Sullivan et al, 2001; Keefe et al, 2005).
Depression, anxiety and sleep disturbance are common in the
cancer patient population. It would therefore seem prudent to
consider these variables when designing cancer pain trials.
The objective of this review was to conduct a systematic
investigation of specific oral opioid (morphine, oxycodone,
hydromorphone) pain trials in adult cancer patients in order to
1. evaluate the general methodological quality of randomised,
controlled trials of opioids in cancer pain
2. identify factors related to poor methodological quality
3. investigate whether psychological factors are routinely ad-
dressed in opioid trials
4. make recommendations for future clinical research on pain
treatment in palliative care
It was decided to restrict the review to oral opioids in order to
have consistency and to minimise variation in the studies,
concentrating on study drugs that behave in a similar manner.
MATERIALS AND METHODS
Search strategy and selection criteria
Search terms were oxycodone, morphine, hydromorphone, cancer,
using the Boolean operators ‘OR’ and ‘AND’. The search was
performed in the Cochrane Central Register of controlled trials
(CENTRAL) (current issue), The Cochrane Database of Systematic
Reviews (current issue), MEDLINE (1966 – January 2005) and
EMBASE (1980 – January 2005). Abstracts and unpublished
reports were not considered. There was no language restriction.
The date of the most recent search (CENTRAL) was 9 November
2005.
All identified records from each of the databases were examined.
Studies in adult patients 18 years and above involving treatment of
chronic cancer pain with specific oral opioid (morphine,
oxycodone or hydromorphone) were considered. The titles and
abstracts of studies were examined independently by two reviewers
(RFB, EK) and potentially relevant studies were retrieved for
assessment for inclusion in the review. Each trial report that
appeared to meet the criteria was independently assessed for
inclusion by three reviewers (RB, CE, EK).
Validity assessment
Study quality (randomisation/allocation concealment; details of
blinding measures, withdrawals and dropouts; overall quality
score) were evaluated using the three item (1–5) Oxford Quality
scale (Jadad et al, 1996). Validity was evaluated using the five item
(1–16) Oxford Pain Validity Scale (OPVS) (Smith et al, 2000).
Scoring was performed independently by three reviewers (RFB, CE,
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Data abstraction
A data extraction form was designed and the following data items
were collected:
1. Publication details,
2. Patient population, number of patients
3. Exclusion criteria
4. Description of pain
5. Psychological variables
6. Design, study duration and follow-up
7. Outcome measures
8. Withdrawals and adverse effects
9. Acknowledgement of pharmaceutical industry
10.Statistics
Study characteristics
Randomised trials, described as double-blind and having either
placebo or active controls were included.
Quantitative data synthesis
This is a qualitative systematic review. Quantitative analysis was
not performed.
Quality of Reporting of Meta-analyses (QUOROM) (Moher et al,
1999) guidelines were followed.
RESULTS
Study characteristics
Thirty-four randomised, double-blinded trials were identified. The
characteristics of the included trials are summarised in Table 1.
Seventeen trials were described as multicentre trials, or enrolled
patients from more than one centre. In one trial, 85 patients were
recruited from 30 general practice, hospital or hospice locations
(O’Brien et al, 1997). A total of seven trials enrolled a hundred or
more patients in each trial. Six of these were multicentre trials with
the number of centres involved ranging from seven to 19. The
maximum number of patients enrolled in any one trial was 180.
This was a multicentre trial involving 17 centres (Kaplan et al,
1998). In general, the multicentre trials recruited larger numbers of
patients than the single-centre trials. The mean number of patients
enrolled in a multicentre trial was 80, more than twice that of the
mean number in a single-centre trial.
Patients
The total number of patients enrolled was 1864. Patients recently
or currently receiving radiotherapy and/or chemotherapy were
specifically excluded in 20 of 34 trials. In two of these trials
(Kaplan et al, 1998; Parris et al, 1998), the protocol was
subsequently changed to facilitate patient inclusion.
Trial design
Twenty-six trials had crossover, and eight had parallel group
design; 26 trials used double-dummy technique. Thirty-three of the
34 trials were equivalency studies.
Only one study (Hoskin et al, 1989) had a placebo control, while
another study had a placebo arm in the first phase (Broomhead
et al, 1997). Only nine studies described the process of
randomisation.
Quality, validity and sensitivity
Quality scores were generally high with a mean of 4, while validity
scores were somewhat lower with a mean of 10 on the OPVS scale
of 1–16.
Only nine trials were scored as sensitive. In the remaining trials,
baseline levels of pain were insufficient to be able to measure a
change following treatment, baseline levels of pain could not be
assessed or internal sensitivity was not demonstrated.
Group size
Six studies had a group size between 10 and 20, while 28 studies
had a group size over 20.
Duration
Ten trials had a duration of 7 days or less. Fourteen trials had a
duration of between 7 and 14 days. Ten trials lasted longer than 2
weeks. The trial with the longest duration lasted maximum 35 days
(Stambaugh et al, 2001).
Withdrawals/dropouts
Twenty-nine studies had a withdrawal/dropout/nonevaluable rate
over 10%, with 12 studies exceeding 30%. Six trials had a
Potential trials identified from titles 
and abstracts
   N = 50 
N = 34
Included trials: randomised, 
double-blind and controlled   
Excluded trials   N = 16 
Not blinded (12) 
Pharmacokinetic study (2)
Duplicate + mixed patient group
(cancer and noncancer) (2) 
Figure 1 QUOROM statement flowchart.
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maximum duration of 28 days and a withdrawal rate of 44%
(Coluzzi et al, 2001). The most common reason for failure to
complete the study was adverse effects, followed by insufficient
pain relief and deterioration due to disease progression. In general,
trials of longer duration had larger numbers of patients who failed
to complete the study. Twenty-four studies had a duration of more
than 1 week, with 16 studies lasting 2 weeks or longer.
Pain description and assessment
Only 11 of 34 studies (Table 1, trials 5, 6, 8, 12, 15, 18, 19, 26, 28, 30,
34) included a description of the pain. In two of these (Deschamps
et al, 1992; Stambaugh et al, 2001), the description was restricted
to the location of the pain. Five trials (Hays et al, 1994; Bruera et al,
1996, 1998, 2004; Hagen and Babul, 1997) evaluated patients using
the Edmonton staging system which classifies pain as visceral,
Table 1 Characteristics of included trials
Trial
No.
patients
enrolled Design Duration
Dropouts/
nonevaluable
(efficacy)
Pain
measures
Quality
score
(1–5)
Validity
score
(1–16)
Psychological factors;
sleep: assessed/reported
1 Boureau et al (1992) 52 (M) Crossover 14 days 8 (15%) VASpi; VRSpi 4 13 Mood, four-point scale;
‘Quality and length of sleep’/mean
group scores reported: ND
2 Broomhead et al (1997) 172 (M) Parallel group.
Placebo control
(first phase)
Max. 22 days 20 (12%) VASpi; VRSpi
VRS pain control
4 15 ‘Quality of sleep’/Final day
group values: ND
3 Bruera et al (1996) 95 (M) Crossover 11 days 21 (22%) VASpi; VRSpi 4 10 ESSCP/NR
4 Bruera et al (1998) 32 (S) Crossover 14 days 9 (28%) VASpi; VRSpi 4 11 ESSCP; ‘poor sleep’/NR
5 Bruera et al (2004) 103 (M) Parallel group 4 weeks 37 (36%) NRSpi 5 15 ESSCP; Folstein Mini-Mental status/
No. of patients having baseline
Mini Mental score X27reported.
Pain data NR
6 Coluzzi et al (2001) 134 (M) Crossover Max. 28 days 59 (44%) NRSpi; VRSpr 5 13
7 Cundiff et al (1989) 23 (S) Crossover 44 days 9 (39%) Nurse rated
VRSpi
41 1
8 Deschamps et al (1992) 20 (M) Crossover 24 days 8 (40%) VASpi; PPI 5 7
9 Finn et al (1993) 34 (M) Crossover,
placebo control
6 days 3 (9%) VASpi 5 13 VAS anxiety; VAS depression/
Mean VAS scores7s.e.m.: ND
10 Gabrail et al (2004) 47 (M) Crossover Max. 30 days 7 (15%) NRSpi 4 15 BPI scores including pain interference
with mood and sleep/Mean (s.d.): ND
11 Gillette et al (1997) 35 (M) Crossover Max. 17 days 15 (43%) VASpi; VRSpi 4 8 ‘Quality of sleep’ and mean
duration of sleep/ND
12 Hagen and Babul (1997) 31 (S) Crossover 14 days 13 (42%) VASpi; VRSpi 4 12 ESSCP/NR
13 Hanks et al (1987) 27 (S) Crossover 4 days 9 (33%) VASpi; VRSpi 4 11 VAS mood; VAS sleep/mean
group VAS scores (s.e.): ND
14 Hanks et al (1995) 25 (M) Crossover 6 days 5 (20%) VASpi 4 8
15 Hays et al (1994) 48 (S) Crossover 14 days 3 (6%) VASpi; PPI 4 13 ESSCP/NR
16 Heiskanen and Kalso (1997) 45 (S) Crossover Max. 33 days 18 (40%) VASpi; VRSpi 5 9 MSDEQ/‘one patient reported
depression, one reported
‘hollow feeling’’
17 Hoskin et al (1989) 19 (S) Parallel group 12 hours 1 (5%) VASpi; VRSpi
VASpr
48
18 Kalso and Vainio (1990) 20 (S) Crossover 8 days 1 (5%) VASpi 3 6 ‘Quality of sleep’/less sleep
disturbance during oral opioid
compared to IV PCA treatment
19 Kaplan et al (1998) 180 (M) Parallel group 6 days 16 (9%) VRSpi 4 11 0/spontaneous report of
nervousness, anxiety
20 Klepstad et al (2003) 40 (S) Parallel group p7 days 6 (15%) VASpi; VRSpi 5 11 ‘Loss of sleep’; HRQOL/HRQOL:
ND; sleep data NR
21 Knudsen et al (1985) 18 (S) Crossover 14 days 2 (11%) VASpi 4 10
22 Lauretti et al (2003) 26 (S) Crossover X35 days 4 (11%) VASpi 4 10
23 Melzack et al (1979) 44 (S) Crossover ‘About’ 4 weeks 14 (32%) PPI 4 9
24 Mignault et al (1995) 19 (S) Crossover 10 days 8 (42%) VASpi; VASpr 4 7
25 Moriarty et al (1999) 100 (M) Crossover Max. 9 days 11 (11%) VASpi; VRSpi 5 15
26 Mucci-LoRusso et al (1998) 101 (M) Parallel group Max. 12 days 20 (20%) VRSpi 5 14 QOL (FACT G)/ND
27 O’Brien et al (1997) 85 (M)* Crossover 14 days 16 (19%) NRSpi 4 12
28 Parris et al (1998) 111 (M) Parallel group 5 days 37 (33%) VRSpi 4 16
29 Portenoy et al (1989) 51 (S) Parallel group Max. 5 days 2 (4%) VRSpi 4 11 ‘Quality of sleep’/ND
30 Stambaugh et al (2001) 30 (S) Crossover Max. 35 days 10 (33%) VASpi; VASr 4 13
31 Thirlwell et al (1989) 23 (M) Crossover X10 days 5 (22%) PPI 4 8
32 Walsh (1985) 36 (S) Crossover,
placebo control
10 days 6 (17%) VASpi 4 10 VAS mood/anxiety/ND
33 Walsh et al (1992) 33 (M) Crossover 6 days 6 (18%) VASpi 5 9 VAS anxiety,
VAS depression/mean
VAS scores: ND
34 Wilder-Smith et al (1994) 25 (S) Crossover 8 days 5 (20%) VRSpi 4 9
(S)¼single centre study; (M)¼multicentre study; pi¼pain intensity; pr¼pain relief; PPI¼present pain intensity (McGill); *not described as multicentre trial, but patients
‘recruited from 30 sites’; BPI¼Brief Pain Inventory; ESSCP¼Edmonton Staging System for Cancer Pain; ND¼no difference between groups; NR¼not reported; VAS¼visual
analogue scale; VRS¼verbal rating scale; NRS¼numerical rating scale.
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nonincidental. However, only three of these trials reported data on
the type of pain.
Pain intensity was assessed in all trials: in nine trials using visual
analogue scale (VAS), in seven using verbal rating scale (VRS) and
in four trials using a numerical rating scale (NRS). Thirteen trials
used VAS in addition to VRS. One trial used a nonvalid
assessment, nurse-rated VRS that was later converted to a
numerical score. Five trials rated pain relief in addition to pain
intensity. In three of these trials, pain relief was assessed using
VAS and in two trials using VRS.
The criteria for adequate/inadequate pain relief was clearly
defined in only eight of the 34 trials. The criteria differed for each
of these trials and for adequate pain relief included: ‘maximum 3
on a 7 point VRS, and not more than two daily requests for rescue
analgesia’ (Klepstad et al, 2003); ‘no need for dose adjustment for
three or more days and no morphine sulphate solution intake
exceeding 50% of the daily morphine dosage supplied by the test
drug’ (Deschamps et al, 1992); ‘no more than three supplementary
doses of immediate release morphine per day’ (Portenoy et al,
1989); ‘required daily rescue doses over 2 days interval not more
than 20% of the total daily morphine doses’ (Cundiff et al, 1989);
‘over a 48-h period, the q12h dose was unchanged, less than two
supplemental analgesic doses were taken per day, the dosing
regimen for any non-opioids or adjuvants was unchanged, and the
patient reported that pain control was acceptable and any side
effects were tolerable’ (Mucci-LoRusso et al, 1998). Inadequate
pain relief was defined as: ‘more than two doses of rescue
medication/24h, or moderately severe global pain score’ (Stam-
baugh et al, 2001); ‘despite dose escalation, pain intensity rating
more than three on a five point VRS’ (Wilder-Smith et al, 1994).
One study defined a clinically meaningful difference in VAS scores
as 25mm on a 100mm scale (Walsh et al, 1992).
Psychological variables and sleep (see Table 1)
Despite the fact that anxiety and depression are known to influence
the perception of pain, only three trials (Walsh, 1985; Walsh et al,
1992; Finn et al, 1993) assessed and reported these variables. In
addition, one of these trials and two others assessed and reported
‘mood’ and a third trial used Brief Pain Inventory (BPI) ratings of
mood and enjoyment of life. A further five trials used the
Edmonton staging system that includes assessment of the degree of
psychological stress in order to calculate a prognosis score, but did
not report data on psychological variables. One of these trials in
addition used the Folstein Mini-Mental status. One trial (Heiska-
nen and Kalso, 1997) used the Modified Specific Drug Effects
Questionnaire (MSDEQ) which includes questions such as ‘Do you
feel anxious?’ and ‘Do you feel relaxed ?’. Mucci-LoRusso et al
(1998) used a quality of life questionnaire, the Functional
Assessment of Cancer Therapy-General (FACT G), which includes
an emotional subscale. Nine trials assessed sleep and seven of these
provided data.
Adverse effects
All trials included data on adverse events. Twenty-five trials
assessed adverse event severity using verbal or categorical rating
scales, or VAS. Eighteen trials provided data from these
measurements.
Adverse effect intensity was rated using VAS in nine trials, NRS
in one trial and by categorical or verbal rating scale in 13 trials.
One trial used both VAS and categorical scales. In one trial, where
severity was investigator-rated, it is unclear which method was
used (Kaplan et al, 1998).
A total of 18 trials provided dichotomous data on the incidence
of adverse effects.
These included all nine studies not grading the intensity of
adverse effects. Only nine of the 25 studies grading adverse effect
intensity provided dichotomous data on incidence.
Statistical methods
The statistical methods used are summarised in Table 2. All 34
trials are judged to have chosen appropriate statistical methods on
most of the analyses; however, some problems were identified
regarding the statistical analysis in 18 trials.
In nine trials (Table 2, trials 1, 4, 10, 12, 15, 19, 20, 25, 33), the
authors concluded that the test drug was equally effective as the
comparator drug. However, the tests performed only show no
evidence of effect, not evidence of no effect.
Only 10 of 34 trials reported to have performed pre-hoc sample-
size calculation. In three trials, some posterior power calculations
were performed (Portenoy et al, 1989; Walsh et al, 1992; Mignault
et al, 1995) and in one study it is unclear whether sample-size
calculation was performed (Stambaugh et al, 2001). In other
words, more than 50% of the trials did not report performing
power calculations.
Sponsored research
The pharmaceutical industry was specifically acknowledged in 24
of 34 trials as follows: co-authors (18 trials) financial support (four
trials), manufacture of placebo double-dummy medication (one
trial) morphine assays (one trial). Twenty-three of these 24 trials
were equivalency studies.
DISCUSSION
This review has identified several factors/areas that could improve
the methodological quality of studies on cancer pain. The findings
of the review also suggest that specific validity scores should be
developed to focus more on factors that are relevant in cancer
pain.
Factors influencing methodological quality
The research question The most commonly asked research
question in these trials is whether one opioid is as good as
another, or whether two forms of administration of the same
opioid are equally effective. However, what we really need to know
is more about factors which influence the cancer patient’s
experience of pain, and which factors influence treatment
outcome. In order to do this, we need to define good and bad
responders and to identify factors that influence treatment
outcome. It is important to understand why some patients do
not achieve pain relief, for example with opioids, and why some
patients respond to one opioid but not to another.
Trial design Thirty-three of the 34 trials in this review are
equivalency (or non-inferiority) studies comparing two opioids or
two or more formulations of the same opioid.
Problems with equivalency trials: In equivalency studies of
analgesics (drug A vs drug B), the focus is a comparison of the
test drug with standard therapy (active control), not efficacy of the
test drug per se. Equivalency trials are potentially problematic
since they do not measure efficacy directly. In such a trial, the
same result is consistent with three possible conclusions (Landow,
2000; Moore et al, 2003):
  Both treatments are equally effective
  Both treatments are equally ineffective
  The trials were inadequate to detect differences between
treatments
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Trial Design Primary outcome Sample-size calculations Type of statistical analyses
Comment on statistical
analyses General comments
1 Boureau et al (1992) CR morphine suspension vs
CR morphine tablets (E)
Pain intensity No sample-size calculations
mentioned
t-test, w
2 test, ANOVA Tests appear appropriate Authors conclude that CRM
suspension is as effective as CRM
tablets. The tests performed show
only no evidence of effect, not
evidence of no effect
2 Broomhead et al,
1997
SR morphine once a day
formulation vs SR morphine
twice daily formulation (E)
Elapsed time to
remedication/total
amount of rescue
medication (mg)
Sample-size calculations performed,
based on results from phase one
ANOVA, Dunnett’s multiple
comparison procedure, w
2 test,
Fisher’s exact test, Cochran-
Mantel–Haenzel chi squared
The adjustment of the significance
level due to large number of
comparisons is appropriate, as are
the statistical analyses
3 Bruera et al (1996) SR hydromorphone vs IR
hydromorphone (E)
Pain intensity No sample-size calculations are
mentioned
ANOVA, Cochran-Mantel–
Haenzel test
Tests appear appropriate
4 Bruera et al (1998) CR oxycodone vs CR
morphine (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Three-way-ANOVA, two-way
ANOVA, w
2 test, Pearson
correlation
Tests appear appropriate Authors conclude that the efficacy
of CR oxycodone is at least equal to
CR morphine. The tests performed
show only no evidence of effect, not
evidence of no effect
5 Bruera et al (2004) Methadone vs morphine (E) Pain intensity Appropriate pre-hoc calculations
appear to have been performed
w
2 test, Pearsons rho, Wilcoxon
rank-sum test, Fisher’s exact test
Tests appear appropriate
6 Coluzzi et al, 2001 OTFC vs IR morphine for
breakthrough pain (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Three-way-ANOVA Tests appear appropriate
7 Cundiff et al (1989) CR morphine vs IR
morphine (E)
Pain intensity No sample-size calculations
mentioned
Two-way ANOVA, parallel line
log-ratio assay (some kind of
ANOVA)
Old reference (Finney), difficult to
distinguish the method from other
ANOVA
8 Deschamps et al,
1992
IR release vs CR release
morphine (E)
Pain intensity No sample-size calculations
mentioned
Repeated-measures ANOVA,
paired t-test
Tests appear appropriate
9 Finn et al (1993) SR morphine tablets
compared with IR
morphine solution (E)
Pain intensity No sample-size calculations
mentioned
Linear regression, McNemars test,
ANOVA
Tests appear appropriate
10 Gabrail et al (2004) ER oxymorphone vs CR
oxycodone (E)
BPI (pain intensity and
interference)
No sample-size calculations
mentioned
Mixed-effects model The authors ignore a trend
because it is stated to be ‘not
clinically significant’. This is not
supported by analyses
Authors conclude that
oxymorphone ER and oxycodone
CR were considered equivalent if
the confidence interval around the
treatment difference included zero.
This kind of two-sided test can only
tell whether the two are different,
not whether they are equivalent
11 Gillette et al (1997) Oral morphine syrup vs SR
morphine capsules (E)
Pain intensity No sample-size calculations
mentioned
Linear regression, Spearman’s rank
order correlation test
A ‘test’ for bioequivalence is
mentioned, however not justified.
Other tests appear appropriate
12 Hagen and Babul
(1997)
CR oxycodone vs CR
hydromorphone (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed l
Three-way-ANOVA, two-way
ANOVA, Fisher’s exact test,
w
2 test, binomial test
Tests appear appropriate
13 Hanks et al (1987) CR morphine vs IR
morphine solution (E)
Pain intensity No sample-size calculations
mentioned
Mann–Whitney U-test, ‘standard
crossover-design nonparametric
techniques’ (two-sample t-test)
Six different outcomes were
tested, no adjustments were
performed
14 Hanks et al (1995) SR morphine tablet
(200mg ) vs two 100mg
tablets (E)
Pain intensity No sample-size calculations
mentioned
ANOVA, Wilcoxon signed-rank
test, trapezoidal method for
AUC, t-test
The statistical analyses seem
appropriate
15 Hays et al (1994) CR hydro-morphone vs IR
hydro-morphone (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Three-way ANOVA Tests appear appropriate Authors conclude that CR
hydromorphone is as effective as IR
hydromorphone. The tests
performed show only no evidence
of effect, not evidence of no effect
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Trial Design Primary outcome Sample-size calculations Type of statistical analyses
Comment on statistical
analyses General comments
16 Heiskanen and Kalso
(1997)
CR oxycodone vs CR
morphine (E)
Pain intensity No sample-size calculations
mentioned
Mann–Whitney U-test, Wilcoxon
signed-rank test, paired t-test, w
2
test, regression analysis, one-way
and two-way crossover ANOVA
Tests appear appropriate. Not
possible to ascertain which tests
used at what time
17 Hoskin et al, 1989 CR morphine+IR morphine
vs CR morphine+placebo
Pain intensity No sample-size calculations
mentioned
Trapezoidal method for AUC,
regression (least squares), t-test
Tests appear appropriate
18 Kalso and Vainio
(1990)
Morphine vs oxycodone (E) Pain intensity No sample-size calculations
mentioned
Wilcoxon signed-rank test, rank-
sum test, t-test, Spearmans rank
correlations, linear regression
Tests appear appropriate
19 Kaplan et al (1998) CR oxycodone vs IR
oxycodone (E)
Pain intensity No sample-size calculations
mentioned
ANOVA (two-way, repeated
measures), Fisher’s exact test,
Kruskal–Wallis test
Tests appear appropriate Authors conclude that CR
oxycodone is as effective as IR
oxycodone. The tests performed
show only no evidence of effect, not
evidence of no effect
20 Klepstad et al (2003) SR morphine vs IR
morphine (E)
Time needed to
achieve pain relief
Appropriate pre-hoc calculations
appear to have been performed
t-test, Mann–Whitney U-test Tests appear appropriate Authors conclude that SRM given
daily and IRM given 4-hourly are
equally effective. The tests
performed show only no evidence
of effect, not evidence of no effect
21 Knudsen et al (1985) SR morphine tablets vs IR
morphine tablets or
suspension (E)
Pain intensity No sample-size calculations
mentioned
Wilcoxon paired rank-sum test Tests appear appropriate Difficult to understand why the
significant finding is not clinically
meaningful
22 Lauretti et al (2003) SR morphine vs SR
oxycodone (E)
Consumption of rescue
medication
No sample-size calculations
mentioned
Mann–Whtiney U-test, Wilcoxon
signed-rank test, w
2 test
Adverse effects analysed with w
2
test, this is not appropriate on
small samples
23 Melzack et al (1979) Brompton mixture vs
morphine (E)
Pain intensity Stated that a subject group of 20 is
substantial in a crossover design. No
sample-size calculations mentioned
t-test, w
2 test Tests appear appropriate No reason stated for choosing P-
value of 0.01, however, several
outcomes were tested, therefore
appropriate to use a lower level
24 Mignault et al (1995) SR morphine (MSC) 8-
hourly vs 12-hourly
administration (E)
Pain intensity Some posterior power calculations
performed
Pairwise t-test, McNemars test Tests appear appropriate
25 Moriarty et al (1999) CR hydromorphone vs CR
morphine (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Koch nonparametric method for
crossover studies, binomial test
Tests appear appropriate Authors conclude that
hydromorphone and morphine are
equally effective. The tests
performed show only no evidence
of effect, not evidence of no effect
26 Mucci-LoRusso et al
(1998)
CR oxycodone vs CR
morphine (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Two-way ANOVA, Kaplan–Meier
and Logrank-test, Fishers exact test,
linear regression
Tests appear appropriate Authors mention Kaplan–Meier
estimate and log-rank test under
‘statistical analysis’. Results of these
analyses unclear
27 O’Brien et al (1997) MXL morphine dosed once
daily vs MST continuous
dosed twice daily (E)
Use of escape
medication
No sample-size calculations
mentioned
Double triangular sequential test,
Koch method for crossover studies,
McNemars test, w
2 test, binomial
test
Stated that the study should have
stopped after 33 patients.
However, continued until 69
patients. This may be against
protocol
28 Parris et al (1998) CR oxycodone vs IR
oxycodone (E)
Pain intensity Appropriate pre-hoc calculations
appear to have been performed
Fisher’s exact test, two-way
ANOVA, two-way ANCOVA
Tests appear appropriate
29 Portenoy et al (1989) SR morphine tablet
(100mg) vs three 30mg
tablets (E)
Pain intensity Some posterior power calculations
performed
t-test, w
2 test, repeated-measures
ANOVA, Fisher’s exact test,
Wilcoxon rank sum test
Tests appear appropriate
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KThis problem may be avoided if the control has previously in the
same patient population been shown to be effective compared to
placebo. This is not the case in cancer pain, as trials having a
placebo control are lacking.
Equivalency trials have important methodological limitations
and must be rigorously performed if they are to produce reliable
conclusions, for example needing substantially more patients than
their placebo-controlled counterparts (Jones et al, 1996). The
majority of trials in this review were underpowered (Figure 1).
Placebo control vs active comparator: Since patients in pain
respond to placebo, we need placebo-controlled trials to reliably
determine opioid efficacy. Many researchers consider that it is
unethical to use a placebo control in trials of cancer pain. However,
it is common to use placebo controls both in acute pain and in
chronic pain trials. Morphine is accepted as the gold standard for
cancer pain treatment, however high-quality placebo-controlled
efficacy data in cancer pain is lacking. Extrapolation of efficacy data
from trials in other patient populations is generally not advised.
Using a placebo-control where possible would also permit
smaller group sizes. We do not suggest that a placebo control
should be used in all cancer pain studies, but that it is feasible in
certain types of trial. While it is not possible to randomise patients
treated with stronger opioids to a placebo group, patients using
weaker opioids may be randomised to a placebo group. Almost
half of the studies included in this review recruited patients being
treated with WHO step 2 (weaker) opioids. In these studies, it
would have been possible to include a placebo-arm, provided the
patients had free access to normal-release opioid as rescue
medication, and using consumption of rescue medication as the
primary outcome measure. This type of study should have a
limited duration, for example 14 days, and should not present
ethical problems since the treatment is similar to the clinical
treatment of breakthrough pain, and would be expected to give
satisfactory pain relief. Indeed, the ethics of using a placebo
control in this kind of design should be compared to the potential
ethical dilemma of exposing seriously ill patients to trials which do
not produce reliable results due to lack of power, sensitivity or
other methodological problems.
Crossover or parallel group?: A crossover design may be useful as
it increases the power of the study and uses the patient as his/her
own control. Crossover trials are important since they can identify
clear patient preferences for one drug over another and suggest
ideas for future research for the mechanisms behind these
differences. Crossover trials should have as short a duration as
possible in order to reduce number of withdrawals, while parallel
group trials allow longer follow-up with regular assessment of
outcomes.
Reporting of data
Since trial size is a general problem, efforts should be made to
enable combination of data from different trials (meta-analysis).
Data should be given as means7s.d., or mediansþrange together
with responder status. The latter will help those who perform
meta-analysis and also enable the researchers to further analyse
the reasons why some patients respond to analgesic drugs and
others do not. Adverse effects should be reported as dichotomous
data. Patient treatment preference is valuable information and
should be recorded. For example, some adverse effects may be
more acceptable than others.
Pain description and assessment
Cancer pain may be constant, intermittent or both. It may
be nociceptive, neuropathic or mixed. It may be cancer-related
or treatment-related. If we are to investigate opioid efficacy,
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British Journal of Cancer (2006) 94(11), 1559–1567 & 2006 Cancer Research UKwe at least need to know what kind of pain is being treated.
In a parallel group study, if there are more patients in one group
having neuropathic pain, then this would be expected to influence
opioid treatment outcome.
As a minimum requirement, each patient included in a pain trial
should be assessed specifically for pain and given a simple pain
diagnosis. A common agreement on what constitutes treatment
effect is important. The fact that the criteria for adequate/
inadequate pain relief were clearly defined in only eight of 34
trials, and differed for each of the trials, indicates a need for
standardisation.
Psychological factors
No trial specifically addressed psychological variables and the
importance of these in the perception of pain. We need to know
whether levels of anxiety and/or depression are similar in
treatment groups, since this may affect outcome. There is a
commonly held belief that the anxiety-reducing and euphoria-
producing components of opioid actions account in large part for
their analgesic efficacy. This would be interesting to explore in the
context of a randomised trial. For example, do psychological
factors such as anxiety and depression improve when pain scores
improve? Is it possible that patients with specific psychological
coping profiles, in particular those who cope anxiously, may have a
poor response to opioid therapy? Studies of specific variables such
as catastrophic thinking about pain (Sullivan et al, 1995) or
acceptance of pain (McCracken et al, 2004) may be fruitful. The
field is recognizing the need to develop assessment techniques that
are specific to the context in which the assessment is performed
(Mystakidou et al, 2005). It is possible to use compound measures
that do not have to be lengthy in this setting. In the absence of any
multidimensional, psychometrically validated assessment tool, the
very minimum requirement would be a unidimensional tool such
as a VAS of severity of anxiety or a VAS of severity of depression.
Other factors influencing opioid treatment outcome
Patients recently or currently receiving radiotherapy and/or
chemotherapy were excluded in 20 of 34 trials. Whether patients
receiving oncological treatment which may influence pain should
be excluded from drug trials on cancer pain depends on the trial
design. In studies of long duration, that is, several days or longer,
including these patients is a confounding factor. In short studies,
for example those examining the effect of short-acting rescue
medication for breakthrough pain, including such patients should
not be a problem.
A number of other factors, including gender, diurnal variation,
pharmacogenetics and opioid pharmacokinetics, may influence the
cancer patient’s experience of pain and the outcome of opioid
therapy. While it is not possible to control for all these variables,
some simple measures are available and useful, such as matching
groups for gender and controlling plasma opioid concentration at
steady state.
Trial funding
The majority of studies were funded by the pharmaceutical
industry. This may represent a source of bias, since research
questions of interest for the industry, for example comparing two
formulations of the same opioid, may not necessarily coincide with
questions of importance for the clinician.
CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE RESEARCH
Pain is a subjective experience that is affected by many different
factors. This makes pain difficult to measure and clinical pain
research a challenge. The challenge is even greater in a palliative-
care setting where there are special standards of care to maintain,
and numerous potential confounding factors.
The data support the clinical experience that it is difficult to
perform high-quality scientific trials in palliative-care pain
patients. However, it is important to maintain scientific rigour
and to ensure that research questions that are relevant to clinical
practice are asked.
A number of methodological problems have been identified,
including low trial sensitivity, too small trial size and lack of
standardised measures of efficacy. Placebo-controlled efficacy
trials of oral opioids for cancer pain are lacking. A placebo
control is feasible in selected trials. It is important to know which
type of pain is being treated and there should be a common
definition of opioid efficacy. Psychological factors can influence
the experience of pain and should be assessed and reported. A
number of other factors have the potential for influencing opioid
response, and future research should involve identifying and
controlling for such factors.
Having analysed the literature we conclude that there is a need
for standardisation and uniformity of design and reporting of
trials. Trials must be designed to produce reliable results. This
cannot be accomplished by a single researcher, but requires the
collaboration of experts in several fields.
The standard opioid trial design
We propose a consensus meeting where pain researchers,
systematic reviewers in pain relief, palliative-care physicians,
oncologists, epidemiologists/statisticians and pain psychologists
are represented. The objective of such a meeting would be to
produce a standard trial design, or set of trials, for opioids in
cancer pain. In addition, a checklist for the performance of trials,
based on tailor-made validity scores for cancer pain (Antczak et al,
1986a,b). The document produced could then be submitted to
specialist organizations which have a focus on trial methodology,
for example the International Association for the Study of Pain
(IASP) and the European Association for Palliative Care (EAPC),
and subject to approval, made available on the respective websites.
The development and dissemination of a standardised trial,
together with checklist for trial performance, will help researchers
to plan trials, improve study quality and validity and enable the
combination of data from separate trials.
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